Skip to main content
Veterinary Medicines

Synulox Palatable Tablets 250 mg

Authorised
  • Amoxicillin trihydrate
  • Potassium clavulanate

Product identification

Medicine name:
Synulox Palatable Tablets 250 mg
Active substance:
  • Amoxicillin trihydrate
  • Potassium clavulanate
Target species:
  • Dog
  • Cat
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Amoxicillin trihydrate
    229.61
    milligram(s)
    /
    1.00
    Tablet
  • Potassium clavulanate
    91.74
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
    • Cat
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01CR02
Authorisation status:
  • Valid
Authorised in:
  • Ireland
Package description:
  • The tablets are circular pink tablets with a breakline on one face and �SYNULOX� engraved on the other. They are packed in laminated aluminium foil strips containing 5 x 2 tablets. 250 mg tablets are in packs of 250
  • The tablets are circular pink tablets with a breakline on one face and �SYNULOX� engraved on the other. They are packed in laminated aluminium foil strips containing 5 x 2 tablets. 250 mg tablets are in packs of 100

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Zoetis Belgium S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Haupt Pharma Latina S.r.l.
Responsible authority:
  • HPRA
Authorisation number:
  • VPA10387/074/002
Date of authorisation status change:

Documents

Summary of Product Characteristics

English (PDF)
Published on: 3/05/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."